Palles foundation for Anders research

Information in Swedish

Welcome to this web-site in memory of my father, who passed away, suddenly and unexpectedly on March 20, 2013, at 68 years old. It was his wish that a foundation be formed in his memory to support the science that I conduct in my laboratory. His faith in me and the work I perform is an amazing declaration of love and a source of inspiration that I will always carry with me.

If you wish to support the scientific research described below, funds can be remitted to “Palles Fond” using bankgiro 165-3575 or if abroad, money can be transferred to the foundation's account in Handelsbanken as shown below. The money in the foundation will be used exclusively to support my research and the Foundation and any questions related to the foundation and its structure can be addressed to

For more detailed information about my research click the research links above, visit my Facebook page or contact me directly using the e-mail address above.

Handelsbanken, Box 166, SE-351 04 Växjö
Clearing no: 6879

Account no: 721 960 618


The research I am conducting and have developed during the last couple of years is focused partly on better understanding how bacteira cause disease, how breastfeeding protects against infections and how we can use this knowledge to treat infections, expecially those caused by antibiotic resistant organisms, in a novel and better way. We are also interested in the effect of breast milk as adjunctive therapy against cancer. Thus, I have developed three areas of research where I sense there is a high potential to develop strategies leading to new agents that can treat patients with severe infections and cancer in the future.

HAMLET, a protein-lipid complex from human milk that kills bacteira and sensitizes them to common antibiotics.
Breast-feeding is well documented to protect against a variety of infections, including a strong protection against respiratory tract infections. During my graduate studies in Dr Catharina Svanborg's laboratory I discovered a protein complex from human milk, HAMLET (human alpha-lactalbumin made lethal to tumor cells) that induced apoptosis in tumor cells without affecting healthy cells. Besides killing tumor cells, HAMLET effectively killed pneumococci, the most common bacterial cause of middle ear infections, pneumonia and the cause of approximately 1.6 million deaths worldwide, 1 million of which are children under the age of 5 (11% of all children that die). HAMLET kills all strains of pneumococci, including those resistant to a variety of antibiotics and one of the major features of HAMLET is the fact that bacteira cannot become reistant to HAMLET. By better undersanding the mechanisms whereby HAMLET kills these bacteira we aim to develop novel antibiotic agents in the future that bacteria cannot become reistant against.

Recently, we also observed that HAMLET had important activities against baceteria that HAMLET alone cannot kill. We have observed that HAMLET can synergize with common antibiotics to make antibiotic-resistant bacteria, such as Staphylococci (MRSA), sensitive to the antibiotics they are resistant to. We can therefore treat infections that are currently hard or impossible to treat clinically. Our current projects are aimed at characterizing the specific network of molecules activated during HAMLET-induced potentiation of antibiotics to develop HAMLET as an adjuvant therapy used in combination with common antibiotics to increase the effectiveness of treatment of infections in the clinic.

New vaccines against bacteiral infections.
We also have a major interest in understanding the bacterial and host interplay during colonization and infection. We have reently shown that pneumococci colonize the nasopharynx as a biofilm and have characterized the factors required for optimal colonization and biofilm formation and how these factors promote fitness of this organism in its natural niche. Pneumococci belong to what we may call our normal flora and in most cases colonize our nasopharynx without inducing any infection. Sometimes changes of this environment trigger bacteira to leave this environment to cause infection. These bacteira are very different than those baceteria colonizing us. The current vaccine development is targeted on eradicating these bacteira from our nasopharynx to avoid infection. However, this may not be the optimal strategy as eradication of normal flora is uaually replaced by organisms that may cause more problems than the organisms that was eradicated. Based on our novel understanding of the molecules involved in the transition from colonization to infection we hope to use those molecules in a vaccine to eradicate only bacteira that cause infection and not those that silently form our normal flora.

Human milk as adjuvant therapy against cancer disease.
Since our discovery of HAMLET's anti-tumor activity I have been in contact with hundreds of cancer patients who have been consuming milk as treatment against their tumors. This regimen has had two effects. The first effect that is common to everyone drinking human milk is that their quality of life improves and that they have less side effects from conventional therapy. This has been documented in a study originating in California. The other effect seen in many patients is a therapeutic effect that has lessened their tumor burden. These anectdotal effects have led us to start the planning of a controlled clinical study where human milk will be used as an adjunctive therapy to conventional therapy. We plan to start this study in a year or two, depending on our ability to raise funds.